Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ragini Kudchadkar"'
Autor:
Aleksandar Sekulic, Simon Yoo, Ragini Kudchadkar, Julie Guillen, Gary Rogers, Anne Lynn S. Chang, Scott Guenthner, Bernard Raskin, Keith Dawson, Yong Mun, Laura Chu, Edward McKenna, Mario Lacouture
Publikováno v:
PLoS ONE, Vol 17, Iss 1, p e0262151 (2022)
PLoS ONE
PLoS ONE, Vol 17, Iss 1 (2022)
PLoS ONE
PLoS ONE, Vol 17, Iss 1 (2022)
Background Limited information is available regarding real-world treatment patterns and their effectiveness and safety in patients with locally advanced basal cell carcinoma, including patients not typically represented in clinical trials. The purpos
Autor:
Peng Sun, Kevin B. Kim, Howard A. Burris, Omid Hamid, Jeffrey A. Sosman, Jonathan Cebon, Alicia Allred, Peter F. Lebowitz, Gerald S. Falchook, Richard F. Kefford, Karl D. Lewis, Daniele Ouellet, Keith T. Flaherty, J. R. Infante, Lynn M. Schuchter, Adil Daud, Rene Gonzalez, Georgina V. Long, Jeffrey S. Weber, Nageatte Ibrahim, Igor Puzanov, Ragini Kudchadkar, Ajay Singh, Alain Algazi, Shonda M Little, Kiran Patel
Publikováno v:
The New England journal of medicine, vol 367, iss 18
BackgroundResistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a s
Autor:
Karl D. Lewis, Nageatte Ibrahim, Igor Puzanov, Kevin B. Kim, Georgina V. Long, D.P. Lawrence, Omid Hamid, Adil Daud, Elizabeth Cunningham, Gerald Steven Falchook, Howard A. Burris, Keith T. Flaherty, Alain Algazi, Lynn M. Schuchter, Jonathan Cebon, Heather Lynn Del Buono, Amy S. Kline, Jeffrey R. Infante, Kiran Patel, Jeffrey S. Weber, Ragini Kudchadkar, Rene Gonzalez, Diane Opatt McDowell, Richard F. Kefford, Peng Sun, Jeffrey A. Sosman
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(8)
Purpose To report the overall survival (OS) and clinical characteristics of BRAF inhibitor–naive long-term responders and survivors treated with dabrafenib plus trametinib in a phase I and II study of patients with BRAF V600 mutation–positive met